Purpose Positron emission tomography (PET) radioligands specific to α 7 nicotinic acetylcholine receptors (nAChRs) afford in vivo imaging of this receptor for neuropathologies such as Alzheimer's disease, schizophrenia, and substance abuse. This work aims to characterize the kinetic properties o f a n α 7 -n A C h R -s p e c i f i c r a d i o l i g a n d , 
F]DBT-10 parent concentrations and metabolism in arterial plasma. Baseline PET scans were acquired for all subjects. Following one scan, ex vivo analysis of brain tissue was performed to inspect for radiolabeled metabolites in brain. Three blocking scans with 0.69 and 1.24 mg/kg of the α 7 -nAChRspecific ligand ASEM were also acquired to assess dosedependent blockade of [ 18 F]DBT-10 binding. Kinetic analysis of PET data was performed using the metabolite-corrected input function to calculate the parent fraction corrected total distribution volume (V T /f P ).
Results [
18 F]DBT-10 was produced within 90 min at high specific activities of 428±436 GBq/μmol at end of synthesis. 
Metabolism of [

Introduction
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels distributed throughout the central nervous system [1] . They are composed of subunits arranged in a pentameric fashion, most commonly in heteromeric α 4 β 2 -and homomeric α 7 -nAChR subtype assemblies [2] . Cerebral α 7 -nAChRs have generated much interest for their role in inflammation [3] , memory, and cognition [4, 5] and have been implicated in psychiatric pathologies including schizophrenia [6] , Alzheimer's disease [7] , depressive disorder [8] , and substance abuse disorders [9, 10] . However, the role of α 7 -nAChRs in these neuropathologies is not yet well understood.
Positron emission tomography (PET) radioligands specific to the α 7 -nAChR provide critical tools for in vivo assay of receptors in disease progression and drug development. A number of α 7 -nAChR radioligands have been evaluated (see [11] for review); however, only two have been advanced to PET imaging in humans (see Fig. 1 ). The first, [ 11 C]CHIBA-1001, exhibited high nonspecific binding and poor specificity for the α 7 -nAChR receptor [14, 15] , with peak target to background ratios of 1.3, limiting its clinical utility. The second, [
18 F]ASEM, exhibited preclinical binding potential (BP ND ) values of 3.9-6.6 with dose-dependent blockade [16] and appropriate kinetic properties for human imaging [17] . Blocking studies with an α 7 -nAChR-selective ligand were conducted to examine specific binding levels. Finally, we conducted an ex vivo study to inspect for radiolabeled metabolites in the brain.
Materials and methods
Subjects
The subjects for this study were four Macaca mulatta (two female animals, 8-15 years old, 7-10 kg; two male animals, 6-12 years old, 10-14 kg). All experiments followed institutional guidelines and were approved by the Yale University Institutional Animal Care and Use Committee. F]fluoride. The solution was mixed and heated at 140°C for 10 min. After cooling, the crude product was diluted with 1.5 ml of the semi-preparative HPLC mobile phase and loaded onto a C18 HPLC column (Phenomenex Gemini, 250 ×10 mm, 10 μm) eluting with a mixture of 40 % MeCN and 60 % 0.1 % triethylamine at a flow rate of 5 ml/min. The product fraction, which eluted at 16-18 min, was collected and diluted in a solution of 200 mg ascorbic acid in 50 ml of deionized water (DI). The solution was then passed through a Waters Classic C18 Sep-Pak cartridge. The Sep-Pak was washed with a solution of 10 mg ascorbic acid in 10 ml of DI water and dried with air. The trapped product was eluted off the Sep-Pak with 1 ml of absolute ethanol followed by a solution of 3 mg ascorbic acid in 3 ml of saline. The combined eluents were passed through a 0.22-μm Millipore membrane filter into a dose vial containing a solution of 7 mg ascorbic Quality control tests were performed by HPLC analysis of the product solution on a Shimadzu HPLC system equipped with both UV and radioactivity detectors to determine the chemical purity, radiochemical purity, and specific activity. HPLC conditions consisted of a YMC C18 column (250× 4.6 mm, 5 μm), with a mobile phase of 45 % acetonitrile and 55 % 0.1 % triethylamine at a flow rate of 2 ml/min. The identity of [ 18 F]DBT-10 product was confirmed by coinjection of the radiolabeled product solution with an authentic sample of DBT-10 and detection of co-eluted UV and radioactive peaks on the HPLC chromatogram.
Radiochemistry
PET scanning procedures
A total of seven PET scans were conducted. Four baseline PET scans were acquired, one for each subject; three were 240 min in duration, while 120 min of PET data were acquired for the terminal study. Three additional blocking scans were acquired in two subjects, with the α 7 -nAChR-specific ligand ASEM given less than 30 min prior to [ 18 F]DBT-10 injection, and PET data were subsequently acquired for 180 min.
On the day of scans, subjects were initially anesthetized with ketamine hydrochloride (10 mg/kg, intramuscular) at least 2 h prior to radiotracer administration. Subjects were then maintained on oxygen and 1.5-3 % isoflurane for the duration of scans. Vital signs were continuously monitored and recorded, including respiration rate, blood pressure, heart rate, and temperature. A venous line for radiotracer administration was placed in the saphenous vein, with an arterial line for blood sampling inserted in a radial or femoral artery on the opposite limb.
A Focus 220 PET scanner (Siemens/CTI, Knoxville, TN, USA) was used for PET data acquisition, which has an intrinsic resolution of 1.4 mm at the center of the field of view. A transmission scan was first acquired using a continuously rotating 137 Cs source for 9 min. [ 
Arterial input function measurement
Radioactivity assay of arterial blood samples was performed with a cross-calibrated well-type gamma counter (Wizard 1480/2480, PerkinElmer, Waltham, MA, USA). Whole-blood samples were assayed and centrifuged (2,930g for 5 min). Supernatant plasma samples were then collected and assayed for radioactivity. Select plasma samples (drawn at 3, 8, 15, 30, 60, 90, 120, 180 , and 240 min post-injection) were analyzed with HPLC to measure the radioligand metabolite profile. For metabolite analysis, plasma samples were mixed with urea to a final concentration of 8 M and filtered through 1.0-μm Whatman 13 mm CD/X filters (GE, Florham Park, NJ, USA). Samples were then analyzed on an adapted, automatic column-switching HPLC system [19] . Upon injection, samples were first eluted through a hand-packed C18 sorbent capture column (Strata-X, Phenomenex, Torrance, CA, USA) with a mobile phase of 1 % MeCN and 99 % H 2 O (v/v) at a flow rate of 2 ml/min for 4 min. The capture column was then back-flushed with a mobile phase of 45 % acetonitrile and 55 % 20 mM ammonium bicarbonate (v/v) eluted through a Phenomenex Gemini-NX analytical column (4.6×250 mm, 5 μm) at a flow rate of 1.65 ml/min. The eluent was collected with a fraction collector (CF-1 Fraction Collector, Spectrum Chromatography, Houston, TX, USA) in discrete 2-min bins and counted with gamma counters.
The fraction of unmetabolized parent compound was measured as the ratio of the eluted parent compound, which had a retention time of~11 min, to the total radioactivity collected. The time course of this parent fraction was fitted to an inverted gamma function and corrected for filtration efficiency. Finally, the input function was calculated as the product of the assayed radioactivity concentration in plasma and the unmetabolized parent fraction.
In addition, the free fraction (f P ) was determined from plasma samples with ultrafiltration techniques. An arterial blood sample (3.0 ml) drawn prior to radiotracer injection was gently mixed with~3 kBq of [ 18 F]DBT-10. After partitioning the plasma from red blood cells via centrifugation, the plasma sample was extracted, loaded onto an ultrafiltration cartridge (Millipore Centrifree UF devices), and centrifuged at 1,228g for 20 min. The free fraction was calculated as the ratio of radioactivity in the ultrafiltrate to the total radioactivity in the plasma sample. Measurements of f P were performed in triplicate for each scan.
Ex vivo [ 18 F]DBT-10 study
A male Macaca mulatta (12 years old, 14 kg) was injected with 183 MBq [
18 F]DBT-10 intravenously, and PET data were acquired for 120 min. The subject was then sacrificed under isoflurane anesthesia with a lethal dose of pentobarbital after a final arterial blood sample was withdrawn. The brain was harvested and dissected, with tissue samples extracted from frontal cortex, cerebellum, hippocampus, thalamus, and putamen. Tissue samples were processed using the same procedures described previously [20] and analyzed with the following HPLC conditions: a mobile phase of 45 % acetonitrile and 55 % 20 mM ammonium bicarbonate (v/v) eluted through a Phenomenex Gemini-NX analytical column (5 μm, 4.6× 250 mm) at a flow rate of 1.65 ml/min (retention time for 18 F-DBT-10:~7 min). 
Anatomical MRI acquisition
High-resolution T1-weighted images were acquired for image co-registration and region of interest (ROI) identification. MRI data were acquired prior to PET image acquisition with a Siemens 3 T Trio scanner, with an extremity head coil in the coronal direction and the following spin echo sequence [echo time (TE)= 3.34 ms, repeition time (TR)=2,530 ms, flip angle=7°, thickness=0.50 mm, field of view=140 mm, image matrix=256× 256×176, voxel size=0.547×0.547×0.500 mm]. Non-brain structures were removed with FMRIB's Brain Extraction Tool (http://www.fmrib.ox.ac.uk/fsl/BET).
Image data processing
Raw list-mode PET data were histogrammed (frames of 6× 0.5 min; 3×1 min; 2×2 min; and N×5 min to scan termination) and reconstructed with Fourier rebinning followed by 2-D filtered back projection, using a 0.15 mm −1 Shepp filter and including corrections for scanner normalization, detector dead time, randoms, and radiation scatter and attenuation. This resulted in a reconstructed image resolution of~3.2 mm. The PET images were then registered to MR image space with a six-parameter rigid body registration [21] . The MR native space was normalized using nonlinear registration to a high-resolution rhesus monkey atlas [22] with BioImage Suite 3.01 (http://www. bioimagesuite.org/index.html). Time-activity curves were extracted by mapping atlas-defined regions to PET native space using the optimal transformation matrices calculated in the registration and normalization steps. ROIs extracted included caudate, cerebellum, cingulate, frontal cortex, hippocampus, occipital cortex, pons, putamen, temporal cortex, and thalamus.
[
F]DBT-10 kinetic analysis
For all PET scans, the primary outcome measures were the total volume of distribution [23] , both uncorrected (V T ) and corrected (V T /f P ) by the plasma-free fraction. Regional V T values were estimated using both one-tissue (1TCM) and two-tissue (2TCM) compartment models (see [24] for review). Model suitability was compared with the corrected Akaike information criterion (cAIC; [25] ). Additionally, the multilinear analysis method (MA1; [26] ) was assessed as a more stable, data-driven analysis method. To visualize [
18 F]DBT-10 images, MA1 was also used to calculate V T on the voxel level.
Receptor occupancies of α 7 -nAChRs by ASEM and [ 18 F]DBT-10 V ND /f P were calculated with occupancy plots using the following equation [27] :
All gray matter regions were incorporated into occupancy plots for this analysis, which assumes uniform α 7 -nAChR occupancy and nonspecific binding (V ND /f P ) in these regions.
Results
Radiochemistry
As shown in Fig. 2 (Fig. 2a) . Purification by semi-preparative HPLC (Fig. 2b) (Fig. 2c) , with specific activities of 369±427 GBq/μmol (n=7) at end of . 3a ). The rate of [ 18 F]DBT-10 metabolism was variable across subjects. Three subjects exhibited fast metabolism, such that~17 % parent radioligand remained in the arterial plasma at 120 min post-injection, while the other subject exhibited 50 % parent fraction (see Fig. 3b ). The calculated parent input functions are shown in Fig. 3c . The free fraction, f P , of [ (Fig. 4) . ]DBT-10 in the brain occurred rapidly, peaking at standardized uptake values (SUVs) of 2.9-3.7 within 30 min post-injection and followed by clearance from the brain (see Fig. 5 ). Highest uptake occurred in the thalamus, and lowest in the regions of cerebellum and pons, with moderate uptake in all other regions.
Compartment modeling revealed variation among subjects of [ 18 F]DBT-10 kinetic properties, likely reflecting differences in metabolism of parent compound. The results are summarized in Table 1 . Analysis of the baseline data from two subjects (M1, M3) indicated good agreement between all modeling methods (1TCM, 2TCM, and MA1 where t*=60 min), with <5 % differences in V T values across methods. In contrast, the third subject's baseline scan (M2) yielded high V T standard errors with the 2TCM (>10 %) and poor model fits with the 1TCM; thus, V T estimates from the MA1 method (t*=60 min) were used for this subject. Estimated K 1 values were consistently fast, averaging 0.64±0.12 ml·cm
across regions. Regional V T values ranged from 28.0 to 72.7 ml/cm 3 for the three subjects, while the free fractioncorrected values (V T /f P ) compared extremely well between subjects, ranging from 193 to 376 ml/cm 3 . For subject M1, a V T /f P map was calculated on a voxel-wise basis to visualize the brain distribution of [ Table 2 . Using the outcome measure V T /f P , a dosedependent blocking relationship was observed. Notably, the rate of [ 
Discussion
The in vivo measurement of α 7 -nAChR binding is a critical goal for investigating neurochemical substrates of psychiatric disorders and the acetylcholine system's role in neuroinflammation. Here, we demonstrate the favorable profile of [ Baseline total distribution volumes (V T , ml/cm 3 ) in brain regions, with and without correction for the free fraction, are shown using two-tissue compartment model (2TCM, left), one-tissue compartment model (1TCM, center), and multilinear analysis (MA1, right) methods. Estimated K 1 values (ml·cm −3 ·min −1 ) from 2TCM analysis, and biases of 1TCM and MA1 to the preferred 2TCM, are also included a Indicates poor model fit, where the standard error of parameter estimates was >10 % distribution of α 7 -nAChRs in the rhesus monkey, accurate quantification of V T /f P with 180-min scans, and dosedependent blockade of specific binding. Thus, this study demonstrates suitable kinetic properties of [ 18 F]DBT-10 for quantification of α 7 -nAChRs in the rhesus monkey.
The radiosynthesis of [
18 F]DBT-10 was carried out manually. The radiotracer was produced in >99 % radiochemical and chemical purity. Specific activities at time of injection were 438 ±436 GBq/μmol (n=6). There was a single batch of radiotracer yielding a modest specific activity of 17 GBq/μmol; however, this dose was administered in the terminal study which was precluded from kinetic analysis, as the shortened data acquisition prevented model convergence during kinetic analysis.
The analysis of arterial plasma following [ We therefore conclude that the detected radioactivity in brain A major factor in data analysis was the dramatic differences in metabolism rates among subjects. Of the four subjects, three exhibited rapid metabolism such that 18-22 % radioactivity in plasma was parent [ Table 2 ). The use of V T /f P to estimate [ 18 F]DBT-10 distribution volumes yielded a dose-dependent decrease in response to ASEM blocking, in good agreement across subjects and between predicted and measured receptor occupancies. Thus, correction for the free fraction of parent in plasma may be critical for accurate quantification of [ 18 F]DBT-10. The use of V T /f P as a more stable outcome measure than V T has been previously reported for PET radioligands in other neurotransmitter systems [29] . Importantly, the [ [16, 17] . Given the factor of 5-10 greater receptor density of α 4 β 2 * relative to α 7 -nAChRs in the rhesus monkey [30] , the relative selectivity of a candidate PET radioligand for these receptors is particularly critical. In vitro data indicated that [ 18 F]DBT-10 had higher affinity and selectivity for the α 7 subunit than [ 18 F]ASEM, including 3.5 times higher selectivity for the α 7 -nAChR over the α 4 β 2 *-nAChR. This motivated the present study to investigate an α 7 -nAChR-specific radioligand with potentially less nonspecific binding. [16, 17] . This initial finding supports the hypothesis that [ the same data processing and analysis techniques to carefully compare their kinetic profiles.
In conclusion, [
18 F]DBT-10 exhibits high levels of reversible specific binding with a kinetic profile suitable for accurate in vivo quantification of α 7 -nAChR availability. Future studies are merited to examine intra-subject variations in metabolism rates and compare with other α 7 -nAChR-specific radioligands. [ 18 F]DBT-10 therefore may be useful for studying the role of α 7 -nAChR in disease-specific paradigms.
